chartexchange

NVCR
NovoCure Limited
stockNASDAQ

Market OpenNov 19, 2026 3:17:46 PM EST
10.62USD-0.979%(-0.11)865,529
10.61Bid10.63Ask0.02Spread
Loading…
Loading…
Healthcare
Medical Devices
CEO
Asaf Danziger
HQ
Saint Helier, Saint Helier, Jersey
Previous Close
$10.73
Beta
1.54
52-Week High
$21.45 2026-07-24
52-Week Low
$9.82 2026-02-09
SMA 50
$14.49
SMA 200
$14.77
Avg. Vol 10D
1.70M
Avg. Vol 30D
1.81M
Avg. Vol 90D
1.56M
Relative Vol
0.47
116.92M
97.39M
12,913,904
0.4100%
2,400,000
77,058
NVCR Profile

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.

NVCR Performance
PeriodPriceDateChangeBeta
1W11.722026-11-12-9.55%1.801
1M14.892026-10-19-28.81%1.222
3M18.202026-08-19-41.76%1.310
6M17.012026-05-19-37.68%0.733
1Y11.452025-11-19-7.42%1.545
2Y16.482024-11-19-35.68%—
5Y103.512021-11-19-89.76%1.413
NVCR Stock Summary

NovoCure Limited (NASDAQ:NVCR) stock price today is $10.60, and today's volume is 860,332. NVCR is down 1.208% today. The 30 day average volume is 1.81M. NVCR market cap is $1.24B with 116.92M shares outstanding.